{"id":"budesonide-salmeterol-azithromycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Gastrointestinal upset (azithromycin)"},{"rate":null,"effect":"QT prolongation risk (azithromycin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is an inhaled corticosteroid that suppresses airway inflammation by binding glucocorticoid receptors. Salmeterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle and improves airflow. Azithromycin, a macrolide antibiotic, has immunomodulatory and anti-inflammatory properties that may reduce mucus production and bacterial colonization in chronic airway disease.","oneSentence":"This combination reduces airway inflammation via corticosteroid and macrolide action while improving bronchodilation through beta-2 agonist stimulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:53.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma with persistent airway inflammation"},{"name":"Chronic obstructive pulmonary disease (COPD) with bacterial colonization"}]},"trialDetails":[{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT00471809","phase":"PHASE4","title":"Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2006-03","conditions":"Asthma","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Budesonide + Salmeterol + Azithromycin","genericName":"Budesonide + Salmeterol + Azithromycin","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces airway inflammation via corticosteroid and macrolide action while improving bronchodilation through beta-2 agonist stimulation. Used for Asthma with persistent airway inflammation, Chronic obstructive pulmonary disease (COPD) with bacterial colonization.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}